NCT03036813View on ClinicalTrials.gov

Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

PHASE3CompletedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
Sickle Cell Disease
Interventions
DRUG

voxelotor

OTHER

Placebo

Trial Locations (62)

123

Muscat

1434

Tripoli

10032

New York

11501

The Bronx

11566

Cairo

15219

Pittsburgh

19107

Philadelphia

20817

Bethesda

20900

Monza

21131

Alexandria

21287

Baltimore

23298

Richmond

27514

Chapel Hill

27710

Durham

27834

Greenville

29425

Charleston

30342

Atlanta

33136

Miami

33342

Mersin

35128

Padua

35205

Birmingham

36693

Mobile

37134

Verona

37232

Nashville

38039

Kayseri

38105

Memphis

44519

Zagazig

46260

Indianapolis

47855

Nairobi

48201

Detroit

60612

Chicago

70112

New Orleans

70808

Baton Rouge

72204

Little Rock

73112

Oklahoma City

75743

Paris

75908

Paris

77030

Houston

94010

Créteil

94609

Oakland

1136044

Beirut

11072020

Beirut

02115

Boston

02118

Boston

07112

Newark

M5G 2C4

Toronto

Unknown

Cairo

JMAAW15

Kingston

42325-00100

Nairobi

59857-00200

Nairobi

144-40600

Siaya

1105 AZ

Amsterdam

3015 AA

Rotterdam

2545 CH

The Hague

01130

Adana

E11BB

London

E96SR

London

SE17EH

London

SE59NU

London

W12 0HS

London

WC1N3BG

London

M13 9WL

Manchester

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03036813 - Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) | Biotech Hunter | Biotech Hunter